Abbott Laboratories
Abbott Laboratories Announces Issuance of Senior Notes to Fund Exact Sciences Acquisition
Summary
On February 23, 2026, Abbott Laboratories announced the issuance of $20 billion in senior notes to fund the acquisition of Exact Sciences Corporation, subject to customary closing conditions. The closing of the sale is expected on March 9, 2026. Abbott intends to use the net proceeds, together with cash on hand and/or additional borrowings, to fund the acquisition consideration, repay certain indebtedness of Exact Sciences, and for general corporate purposes. The announcement includes forward-looking statements regarding the acquisition, which involve risks and uncertainties.
Get alerts for ABT
Be first to know when Abbott Laboratories files with the SEC.
Filing Categories
Advertisement
About Abbott Laboratories
Abbott Laboratories, a globally renowned company, specializes in the development and production of healthcare and medical products. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is a pivotal entity in the healthcare sector. The company provides essential products spanning diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. Notably, Abbott's extensive diagnostic solutions include immunoassays and molecular diagnostics, crucial for medical testing and healthcare management. Its medical devices division produces cardiovascular and neuromodulation products, enhancing patient care across diverse medical practices. Abbott’s nutritional segment, featuring well-known brands like Similac and Ensure, supports health and wellness across various demographics. Serving markets globally, Abbott Laboratories plays a critical role in advancing healthcare infrastructure and delivering innovative solutions that address evolving health challenges worldwide. As a significant player in the life sciences field, Abbott's contributions significantly influence patient outcomes and healthcare delivery systems.
Official SEC Documents
Advertisement